New baldness treatment could change the game
Technology
A new topical drug called clascoterone just showed up to a 539% improvement in hair growth relative to placebo in phase III trials for male pattern baldness.
If the FDA gives it the green light next year, this would be the first fresh option for hair loss in decades—pretty big news for anyone tired of old-school treatments.
How clascoterone stands out
Clascoterone works by blocking hormones that trigger hair loss, and trials with nearly 1,500 men found it safe and well-tolerated.
It's already approved as an acne treatment, showing its versatility.
Cosmo Pharmaceuticals plans to wrap up a year-long safety study by spring 2026 before pushing for US and EU approval.